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subjects with high speed Internet capability in their home. Before
initiating virtual visits, the study team determined which activities
could be completed remotely. An encrypted virtual video platform
provided confidentiality and privacy. Before the virtual research
visit, a test visit was completed to familiarize subjects with remote
research processes. Instructions on using the virtual visit platform
were sent ahead of time, including a study team contact telephone
number in case problems arose during connecting. Test visit
activities included assessment of audio/video quality and evalua-
tion of the home study site. A quiet space, free of distractions and
interruptions in the subject's home was selected with sufficient
lighting and appropriate space and positioning for assessment.
Seating position was optimized to enhance the examiner's view of
the subject's face and body, as body language could be missed over
video. For the research visit, eConsent was obtained utilizing
REDCap, a secure website which allowed for synchronous consent
review and sign off. Study team members were scheduled to join
at certain times or kept in a virtual “waiting room” until they were
needed to reduce visit disruptions. Some subjects opted to
complete portions of the visit at different times of the day. In the
6 months since the beginning of pandemic restriction, we com-
pleted 19 virtual study visits across two separate research
protocols. Virtual visit activities have included neurologic exam,
neuropsychological assessment, and administration of a disease-
specific rating scale. Future goals include use of wearable devices
and biometric assessments in the home environment. Virtual visits
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Mucopolysaccharidoses (MPS) are lysosomal diseases character-
ized by defects in the activity of lysosomal hydrolases involved in
glycosaminoglycan degradation, with progressive multisystemic
involvement. Neurological damage is present in MPS I; MPS II; MPS
IIIB, and MPS VII. Using biological networks for searching for genes
with functional relevance give us clues about pathophysiological
mechanisms of neurological diseases. The aims of this work was to
identify potential biomarkers for neurological impairment in differ-
ent types of MPS using public available transcriptomic data. The most
relevant proteins in the networks and ontology terms related to
neurological damage in MPS were identified and compared among
diseases. We performed the clustering analysis for GSE111906
(MPSI), GSE95224 (MPSII), GSE23075 (MPSIIIB), GSE15758
(MPSIIIB), and GSE76283 (MPSVII). Regarding biomarker discovery
analysis, the top 10 genes were ranked according to the maximal
clique centrality. Different ontologies were present in the different
types of MPS. For instance, for MPS I, the related ontologies were
clathrin derived vesicle budding and clathrin-mediated endocytosis.
MPS II top genes were related to brain renin-angiotensin system.
MPS IIIB top genes comprises the ontologies acetylation and
chromatin regulation. The MPS IIIB top 10 genes were related to
the activation of the mRNA cap-binding complex. Finally, MPS VII top
genes were present in the ontologies C-MYB transcription factor
network. Moreover, we identified several immune system processes
like adaptive and innate immune systems, Class I MHC mediated
antigen processing and presentation; and activated TLR4 signaling
across the different MPS types. Other ontologies were also present in
all the MPS types, like axon guidance, Calcium signaling, PI3K-Akt
signaling pathway, and Wnt signaling pathway. We hypothesize that
these pathways are deranged because glycosaminoglycans play an
essential role in the extracellular matrix composition, helping to
regulate several processes. System biology approaches may help to
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Introduction
GD and ASMD are lysosomal disorders caused by deficiency of
lysosomal enzymes acid beta-glucosidase and acid Sphingomyelinase.
These enzyme deficiencies cause accumulation of glucocerebroside and
sphingomyelin, respectively, mainly in macrophages, inducing deterio-
ration of the organs in which they accumulate. Theoretical prevalence of
ASMD is 0.4 per 100,000 and GD is 1 per 40,000 inhabitants. The
absence of epidemiological studies in Spain lead us to believe that ASMD
is highly underdiagnosed, and that the incidence of GD data is still to be
defined.
Aim
To put in place a national medical education program to increase
knowledge of the pathophysiology of ASMD and GD, as well as
dissemination of diagnostic algorithms for these diseases. An epidemi-
ological study of unknown origin splenomegaly was planned as a 3–5
years retrospective search and as a 2 years prospect for new patients,
implementing the diagnostic algorithms defined for both, ASMD and GD.
The epidemiological results obtained will be analysed.
Methods
A total of 52 HCPs (22 Hematologists / 18 Internal Medicine / 12
Pediatricians) from 34 hospitals in Spain are implementing the medical
education program and epidemiological searching in their health area of
influence for two consecutive years. It is planned to impart about 100
clinical sessions within the medical education program and reach 200
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patients fulfilling diagnostic criteria for ASMD and GD in the recruitment
process.
Results
In the first 6months of the project, 12 educational sessions were
held with more than 220 assistants (1 GD patient diagnosed) and 39
patients with diagnostic criteria were reviewed with the result of 1
positive for ASMD and 3 positives for GD.
Comments
Medical education plan and epidemiological study have increased
awareness of these conditions allowing the diagnosis of new patients
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Mucopolysaccharidosis (MPS) type I is a lysosomal disorder
caused by mutations in the IDUA gene and resultant deficiency of
lysosomal α-L-iduronidase (IDUA) enzyme. Patients with severe MPS I
have mutations encoding completely inactive IDUA enzyme, and have
early-onset developmental delay and cognitive regression in addition to
multisystemic manifestations. Treatment for severe MPS I involves
intravenous recombinant human IDUA (rhIDUA) enzyme infusions
followed by stem cell transplant (SCT). However, SCT carries risks of
engraftment syndrome, graft failure, graft-versus-host disease, death,
and potentially incomplete correction of neurodevelopmental manifes-
tations. We will report one-year follow-up in a child with severe MPS I
(IDUA p.R628*/R628*, absent IDUA activity) treated with intracisternal
RGX-111 (recombinant adeno-associated virus serotype 9 capsid
containing the human IDUA expression cassette – AAV9.CB7.hIDUA) at
age 21months utilizing a single-patient investigator-initiated investiga-
tional new drug application, due to two MPS I-affected older siblings
having died of SCT-related complications. Following baseline volumetric
brain imaging, the child received a dose of 1 × 1010 genome copies/g
brain mass. Prednisone (12weeks), tacrolimus (32weeks), and
sirolimus (48weeks) were administered. As of 8months after dosing,
the child has experienced no drug-related serious adverse events.
Cerebrospinal fluid (CSF) biomarkers indicated increased IDUA activity
(12weeks) over baseline levels below the limit of quantification. High
heparan sulfate (HS) levels in CSF were measured at baseline, and initial
data demonstrated sustained decreases in total HS levels with a 50%
reduction from baseline at Week 12 and a 45% reduction from baseline
at Week 33. At Week 32 post-administration of RGX-111,
neurocognitive evaluations indicated that the patient, who was then
29months of age, continued to acquire cognitive developmental skills at
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Acid sphingomyelinase (ASM) deficiency (ASMD) is a rare and
debilitating lysosomal disease with no available treatment. ASCEND
(NCT02004691/Sanofi Genzyme) is a Phase 2/3, multicenter, ran-
domized, double-blind, placebo-controlled trial of olipudase alfa
(recombinant human ASM) enzyme replacement therapy in 36
adults with chronic visceral ASMD. Inclusion criteria included spleen
volume ≥ 6 multiples of normal (MN), percent-predicted diffusion
capacity for carbon monoxide (DLco) ≤ −70%, and abnormal (≥5)
Splenomegaly Related Score (SRS, a patient-reported outcome).
Patients were randomized 1:1 to placebo or olipudase alfa (intrave-
nous every 2 weeks with a ~ 16-week dose-escalation from 0.1 to
3.0 mg/kg or maximum tolerated dose). Independent primary
efficacy endpoints were percent change in percent-predicted DLco
and percent change in spleen volume MN (for the USA, combined
with change in SRS) at Week 52. Other endpoints included percent
change from baseline in liver volume, platelet count, lipids,
chitotriosidase, and lyso-sphingomyelin. Least-square (LS) mean
differences at Week 52 between olipudase alfa and placebo groups
favored olipudase alfa for percent predicted DLco (+22.0% vs. +3.0%,
p= 0.0004), spleen volume (−39.4% vs +0.5%, p b 0.0001), liver
volume (−31.7% vs. 1.4%, p b 0.0001) and platelets (+16.8% vs
+2.5%, p= 0.019), with clinical differences seen by Week 26. SRS
decreased in both groups (−8.0 for olipudase vs −9.3 for placebo at
Week 52, p= 0.70). LS mean differences from baseline to Week 52
favored olipudase alfa for HDL (33.5%, p = 0.0016), LDL (−25.9%,
p = 0.0021), and chitotriosidase (41.9%, p= 0.0003). Pre-infusion
mean plasma lyso-sphingomyelin decreased by 78.0% and 6.1% at
Week 52 in olipudase-alfa and placebo groups, respectively.
Olipudase alfa was generally well-tolerated with an acceptable safety
profile. Most adverse events (AEs) were mild to moderate. There
were no treatment-related serious AEs and no AE-related discontin-
uations. The study showed significant improvements in clinically
relevant disease endpoints at Week 52 in adults with chronic ASMD
treated with olipudase alfa compared to placebo.
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